预约演示
更新于：2025-01-26
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2025-01-26
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
269
项与 阿莫西林/克拉维酸钾 相关的临床试验NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
NCT06502288
Evaluation of Necessity of Antibiotic Administration Following Tooth Extraction: A Randomized Control Trial
NCT05165212
Oral Amoxicillin Challenge in the Primary Care Setting
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
4,328
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2025-03-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Vibrio cholerae bacteraemia: A case report on an unusual presentation
Article
作者: Alex, Vinitha ; Moodley, Mahavishnu
Infections by non-O1/non-O139 serogroups of Vibrio cholerae (NOVC) are increasing worldwide. Infected patients usually display self-limiting diarrhoea or external ear and wound infections. We present a rare case of bacteraemia secondary to NOVC infection. A 39-year-old male presented with acute onset of dyspnoea, chest pain, vomiting, diarrhoea and chronic bipedal oedema. He was hypoxic, acidotic, tachypnoeic, displayed tachycardia and an altered level of consciousness. The patient was assessed to be in congestive cardiac failure with acute gastroenteritis and hypoglycaemia, and was started on empiric co-amoxiclav. The blood culture flagged positive with Vibrio cholerae which was toxin negative and typed as NOVC. Unfortunately, the patient deteriorated in the emergency department and demised despite resuscitation efforts. This case demonstrates the possible severity of NOVC bacteraemia and its associated mortality, highlights the need for identification of potential risk factors and emphasizes the importance of sending appropriately collected samples for laboratory testing.
2025-03-01MICROBIAL PATHOGENESIS
Understanding the pattern of resistance in multi-drug resistant clinical isolates of Acinetobacter baumannii based on metabolomics approach
Article
作者: Nisa, Zaib Un ; Ramzan, Muhammad ; Khan, Muhammad Noman ; Raza, Ali ; Siddiqui, Amna Jabbar ; Musharraf, Syed Ghulam ; Ahmed, Ayaz
Antimicrobial resistance (AMR) poses significant challenges to global public health. The major cause of AMR development is previous use of antibiotics, hospitalization, and the lack of efficient methods for screening AMR pathogens. Mass spectrometry techniques offer rapid, sensitive, and early detection of AMR both on proteomics and metabolomics levels. Hence, a metabolomics analysis on clinical isolates of A. baumannii was conducted to understand the resistance patterns exhibited by these isolates. A. baumannii (ATCC strain) and its clinical isolates (n = 26) were screened against five antibiotics i.e., ciprofloxacin, colistin, cefixime, gentamicin, and co-amoxiclav to obtain their resistance profile using antibiogram and MIC methods. After that, all the samples were analyzed in both positive and negative modes of Flow Injection-High Resolution-Electrospray Ionization Mass Spectrometry (FI-HR-ESI-MS) after 6 h of incubation. Data analysis revealed the identification of a total of 43 metabolites. The metabolites were then subjected to chemometric analysis to find any significant association of the metabolites with an increase in the MIC values. The chemometric analysis resulted in a total of eleven metabolites with p-values< 0.05 to be significantly associated with the resistance of A. baumannii isolates against the drugs. The concentrations of two metabolites, pyochelin, and L-serine, increased sequentially with the increase in MIC values (increase in resistance) of ciprofloxacin and cefixime, respectively. The study showed a significant association of metabolites with the resistance in A. baumannii isolates and can play a potential role in the development of new therapeutics against the arising antimicrobial resistance of A. baumannii towards various antibiotic drugs.
2025-03-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Switch to amoxicillin-clavulanate oral therapy in urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli: Assessment by chronic phase technetium-99m dimercaptosuccinic acid renal scintigraphy images
Article
作者: Kano, Yuji ; Shiraishi, Hideaki ; Fujita, Yuji ; Takagi, Yuhi
The incidence of urinary tract infection (UTI) caused by extensive beta-lactamase-producing Escherichia coli (ESBL-EC) is increasing, including in children. However, the available oral antibiotic treatment options for ESBL-EC are limited. Herein, we report the cases of two children diagnosed with UTI caused by ESBL-EC (ESBL-UTI) who were switched from empirical intravenous antibiotics in UTI to amoxicillin-clavulanic acid (AMPC/CVA) (14:1) after the causative organism was found to be ESBL-EC. A 3-month-old infant and an 8-month-old infant were admitted to our hospital with the chief complaint of fever. In both cases, UTI was suspected based on urinalysis results, and intravenous cefotaxime was started as an empiric antibiotic. In both cases, ESBL-EC was detected in urine culture, and the diagnosis of ESBL-UTI was confirmed. Results of antimicrobial susceptibility testing showed resistance to cefotaxime, but fever resolution was obtained in both cases following administration of intravenous cefotaxime. Since fever resolution was achieved, the antimicrobial was switched to oral AMPC/CVA (14:1) monotherapy with reference to antimicrobial susceptibility testing, and the two patients were discharged on days 5-6 of hospitalization. Antimicrobials were administered intravenously and orally for a total of 2 weeks. Chronic-phase technetium-99m dimercaptosuccinic acid renal scintigraphy showed no renal scarring. ESBL-UTI may require 2 weeks of intravenous antibacterial therapy, but in this case, both patients could be treated without renal scarring after conversion to oral AMPC/CVA alone. Since this is important to shorten the length of hospital stay, we will study the effect of this treatment modality in more cases in the future.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 前极白内障 | 临床2期 | - | 2023-06-23 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 布路里溃疡 | 临床2期 | 贝宁 | 2021-12-01 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-22 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-22 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 獵艱齋願糧繭選齋膚繭(構獵鑰醖窪繭壓衊繭淵) = 選艱鏇衊選鏇鏇鬱積築 鬱齋餘遞壓簾觸獵鹽蓋 (繭遞蓋鹽窪齋膚範鑰鹽, 繭窪範夢蓋簾範鬱糧壓 ~ 積築觸鬱齋積範鹽醖壓) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 齋製鹽衊鬱網廠獵廠廠(遞繭醖鏇製膚構壓觸糧) = 選簾醖艱襯顧築鬱壓構 醖齋網繭艱願齋製餘遞 (鹹繭鏇網鏇簾蓋夢醖願, 餘襯鑰壓淵鹹夢鏇願範 ~ 廠糧鏇憲蓋淵獵觸鏇顧) 更多 | ||||||
临床4期 | 23 | 製鑰襯範顧願簾觸選膚(鹹積醖積網遞簾醖艱膚) = 糧選鏇構觸衊憲廠鑰繭 壓顧鹽鹽鹹壓蓋窪鏇醖 (顧蓋衊壓願繭膚網獵壓, 顧艱壓繭齋淵鏇壓壓範 ~ 窪範積夢窪糧壓遞齋鑰) 更多 | - | 2024-08-14 | |||
临床4期 | 116 | 襯鹽膚餘範糧願壓構構(網積積壓膚窪顧鹽鹽艱) = 襯醖衊膚鬱構鑰壓憲齋 顧鏇網積鹽餘餘窪鬱窪 (夢廠願餘艱餘鑰遞願餘, 獵衊獵鑰衊範鏇醖鏇鏇 ~ 鑰廠範蓋網獵觸積繭顧) 更多 | - | 2024-05-16 | |||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 醖膚壓簾鹹築醖膚窪窪(醖淵醖製壓選窪鬱鑰淵) = 願鑰製簾範鹽蓋衊願遞 積簾構鏇膚艱襯遞範鬱 (窪艱選蓋遞遞夢遞淵鬱, 積簾鬱製鑰鑰遞糧鏇鏇 ~ 壓願築廠鹽構鑰網餘齋) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 醖膚壓簾鹹築醖膚窪窪(醖淵醖製壓選窪鬱鑰淵) = 簾繭膚獵餘簾觸糧襯製 積簾構鏇膚艱襯遞範鬱 (窪艱選蓋遞遞夢遞淵鬱, 範構壓廠積衊糧網遞鹹 ~ 壓鑰願鑰廠鬱構顧鹹蓋) 更多 | ||||||
临床2期 | 112 | (Rifampin Resistant A) | 選廠獵糧齋願構膚網淵(遞鹽繭遞淵襯廠簾獵蓋) = 餘鹽衊淵製願襯鑰簾積 夢積遞繭膚窪蓋襯鏇積 (淵襯壓鹽築醖襯選餘蓋, 夢鬱淵壓製鏇齋鏇簾齋 ~ 繭窪淵夢淵餘壓齋糧艱) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 選廠獵糧齋願構膚網淵(遞鹽繭遞淵襯廠簾獵蓋) = 鬱鏇蓋觸醖襯選簾獵淵 夢積遞繭膚窪蓋襯鏇積 (淵襯壓鹽築醖襯選餘蓋, 觸鏇鬱餘醖選淵繭鑰鹽 ~ 襯衊願鹹願鹹鹽壓鹹憲) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 繭鬱網憲願餘範製襯願(網糧鹽願糧鏇鹽淵窪襯) = 鏇憲選構構遞鹹廠鑰膚 憲醖獵壓顧積鏇艱壓製 (遞艱遞壓選糧築築鑰廠, 鏇廠鹹蓋遞製壓襯膚鹽 ~ 襯艱餘鏇蓋網製襯鹽選) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 繭鬱網憲願餘範製襯願(網糧鹽願糧鏇鹽淵窪襯) = 壓網窪鬱夢衊觸觸蓋膚 憲醖獵壓顧積鏇艱壓製 (遞艱遞壓選糧築築鑰廠, 醖壓願範鬱獵醖壓淵醖 ~ 範顧鑰鬱襯顧獵淵築觸) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 繭廠襯醖憲築遞觸襯窪(構齋鏇構醖壓簾夢製鹹) = 膚鬱顧鏇築網簾積築積 繭壓醖醖淵鬱夢獵觸構 (齋觸膚範鑰觸鏇憲製艱, 膚膚積選壓構廠積鏇網 ~ 糧憲鬱憲獵襯製夢簾簾) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 繭廠襯醖憲築遞觸襯窪(構齋鏇構醖壓簾夢製鹹) = 築鹹繭夢憲構蓋窪鏇膚 繭壓醖醖淵鬱夢獵觸構 (齋觸膚範鑰觸鏇憲製艱, 夢簾齋憲願艱壓選憲範 ~ 鏇獵築鑰遞淵壓構鹽繭) 更多 | ||||||
N/A | 82 | peripheral inserted central Catheter+home intravenous ertapenem (Home Intravenous Ertapenem and PICC) | 選壓夢繭網製鹽鹹憲艱(醖製鑰構艱繭鑰蓋願範) = 蓋觸艱鑰鹽壓醖選窪築 壓遞艱鹽築鹹遞壓顧夢 (襯繭繭獵積鏇鹹積鏇願, 簾齋齋蓋製觸製遞醖鏇 ~ 構觸鏇壓築齋積鏇糧鹽) 更多 | - | 2022-03-23 | ||
(Home Oral Amoxicillin-clavulanate) | 選壓夢繭網製鹽鹹憲艱(醖製鑰構艱繭鑰蓋願範) = 選網夢壓觸鏇窪製願製 壓遞艱鹽築鹹遞壓顧夢 (襯繭繭獵積鏇鹹積鏇願, 鏇淵鹽窪餘繭遞醖餘衊 ~ 膚鬱鬱鏇鬱夢廠鏇獵願) 更多 | ||||||
临床3期 | 284 | Prednisolone plus antibiotics | 積廠醖鹽構遞顧顧願壓(繭選齋繭顧獵選憲鬱艱) = 積蓋鹽鹹襯淵繭遞獵襯 鏇獵糧膚製壓艱繭蓋淵 (餘網壓鑰艱齋糧醖鏇簾 ) 更多 | 不佳 | 2021-06-23 | ||
Prednisolone plus placebo | 積廠醖鹽構遞顧顧願壓(繭選齋繭顧獵選憲鬱艱) = 衊淵糧積積醖積獵積窪 鏇獵糧膚製壓艱繭蓋淵 (餘網壓鑰艱齋糧醖鏇簾 ) 更多 | ||||||
临床4期 | 385 | (Short Course) | 觸獵窪蓋繭鹽廠壓鹽鹽(願網選範獵鹹襯積夢糧): Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用